- Drugs
- Friday, 22 May 2020
Hikma receives FDA approval for its generic Vascepa®
Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, has announced that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received approval from the US Food and Drug Administration (FDA) for its Icosapent Ethyl Capsules, 1 gm, the generic equivalent to Vascepa®1.
In March 2020, the United States District Court for the District of Nevada invalidated six key Vascepa® patents owned by Amarin. The District Court decision is currently being appealed.
Brian Hoffmann, President of Generics said, "The approval for our generic version of Vascepa® is an important milestone towards bringing this product to market. This approval demonstrates the strength of our regulatory capabilities and our commitment to provide patients and healthcare providers in the US with the high-quality medicines they need."
| Enquiries | |
| Hikma Pharmaceuticals PLC | |
| Susan Ringdal | +44 (0)20 7399 2760/ +44 7776 477050 |
| EVP, Strategic Planning and Global Affairs | |
| Steve Weiss | +1 732 720 2830/ +1 732 788 8279 |
| David Belian | +1 732 720 2814/+1 848 254 4875 |
| US Communications and Public Affairs |
Related Industry Updates
Progenics and Curium Announced European Collaboration for Prostate Cancer Imaging Agent PyL
Sep 03, 2019
Vaccines: A Powerful Panacea to Impound Epidemic
Aug 19, 2019
Middle East and Africa Botulinum Toxin Market is expected to reach US$ 453.55 million by 2030
Dec 06, 2023
DisposeRx Adds New Community Outreach Partners to Stop Prescription Drug Abuse
Jun 10, 2020
Aquatic Veterinary Market is expected to reach US$ 1,934.33 million by 2030
Feb 19, 2024
Transdermal Medical Patch Market is expected to reach US$ 10,799.74 million by 2028
Jun 06, 2023
Advancements in Healthcare industry is driving More R & D for Subcutaneous Drug Delivery
Oct 04, 2019
Follow us on
